CompletedPhase 1NCT01006798

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Studying Avian influenza

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Emergent BioSolutions
Principal Investigator
Marc Gurwith, M.D., J.D.
Emergent BioSolutions
Intervention
Placebo(other)
Enrollment
166 enrolled
Eligibility
18-40 years · All sexes
Timeline
20092011

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01006798 on ClinicalTrials.gov

Other trials for Avian influenza

Additional recruiting or active studies for the same condition.

See all trials for Avian influenza

← Back to all trials